A guide to oral micronized progesterone (Prometrium) dosing for adults aged 50 to 64, covering continuous and cyclic regimens, endometrial protection, side-effect management, and guideline recommendations.
What the Prometrium label says about CYP3A4 and progesterone metabolism, variable levels, the food effect, and PROGINS receptor lab findings.
A clinician-oriented guide to oral micronized progesterone (Prometrium) dosing, pharmacokinetics, and monitoring considerations in patients with chronic kidney disease or renal impairment, with an evidence-boundary review and a dosing decision framework.
A complete guide to TRICARE coverage, formulary tier, prior authorization criteria, step therapy requirements, and appeal strategies for oral micronized progesterone (Prometrium) used in hormone therapy.
A clinical and insurance guide to UnitedHealthcare coverage, prior authorization, step therapy, formulary tier, and appeal strategies for oral micronized progesterone (Prometrium).
A clinician-level review of oral low-dose minoxidil for hair loss in patients with autoimmune conditions, covering drug interactions, immune effects, cardiovascular monitoring, and prescribing guidance.
A clinical guide to Cigna coverage, prior authorization, formulary tier, step therapy, and appeal strategies for oral minoxidil for hair loss.
Low-dose oral minoxidil runs about $15 to $50 a month compounded, versus $10 to $20 for generic finasteride. See how the costs and effects compare.
No oral minoxidil is FDA-approved for hair loss, and no pipeline formulation is documented; a 2018 pilot of 100 women tested one combination.
A guide to Kaiser Permanente's formulary status, prior-authorization criteria, step-therapy requirements, and appeal process for oral minoxidil used to treat androgenetic alopecia.
A deep dive into the oral minoxidil patent history, generic availability, compounding status, mechanism of action, and low-dose dosing evidence for androgenetic alopecia.
Evidence-based guide to stopping oral minoxidil before surgery, covering the pharmacology behind the hold window, cardiovascular risks, anesthesia interactions, and when to restart dosing post-operatively.
A deep-dive into how low-dose oral minoxidil affects sexual function, libido, and erectile health. Covers trial data, mechanisms, risk stratification, and clinical guidance for patients considering oral minoxidil for hair loss.
A complete clinical guide to monitoring young adults aged 18 to 29 on low-dose oral minoxidil for hair loss, covering baseline labs, cardiovascular checks, fluid retention, fertility considerations, and visit schedules.
A guide to stopping Ozempic (semaglutide 0.5 to 2.0 mg) safely, covering tapering strategies, rebound risks, glycemic monitoring, and what to expect after your last dose.
Ozempic's cardiovascular indication covers adults with type 2 diabetes and CVD. The 20% MACE reduction in SELECT used semaglutide 2.4 mg, not Ozempic.
Can Ozempic (semaglutide 0.5 to 2.0 mg) help with menopause-related weight gain? Review the trial evidence, dosing schedule, side effects, and how clinicians combine it with HRT.
A guide to using semaglutide (Ozempic) for metabolic syndrome, covering trial evidence, off-label dosing, cardiovascular outcomes, and what to expect week by week.
A guide to using semaglutide (Ozempic) for NAFLD and MASLD, covering trial evidence, off-label dosing, liver-fat outcomes, and how it compares to resmetirom.
Can semaglutide (Ozempic) treat obstructive sleep apnea? A look at what the weight-loss trial evidence does and does not show, how Ozempic differs from Wegovy and the FDA-approved OSA drug Zepbound, and what questions remain unanswered.
A guide to using semaglutide (Ozempic) for prediabetes, covering clinical trial evidence, off-label dosing protocols, side effects, and insurance considerations.
A clinician-level guide to the complete Ozempic (semaglutide 0.5 to 2.0 mg) monitoring schedule: which labs to order, when to order them, what targets to aim for, and which exams cannot be skipped.
A breakdown of Ozempic (semaglutide 0.5 to 2.0 mg) regulatory approvals across the US, EU, Canada, and UK, including approval dates, indications, dose limits, and the evidence base behind each authorization.
An evidence-based guide to using semaglutide 0.5 to 2.0 mg (Ozempic) in transplant recipients, people living with HIV, CKD, hepatic impairment, older adults, and other complex populations. Includes mechanism, dosing considerations, drug interactions, and what the trial evidence does and does not show.
A breakdown of AOD-9604's legal status in Louisiana, covering FDA classification, 503A/503B compounding rules, the Louisiana Board of Pharmacy, and how patients can legally access the peptide.
A guide to AOD-9604's federal and Maryland-specific legal status, including FDA scheduling, 503A/503B compounding rules, and how to get a legitimate prescription.
A guide to AOD-9604's federal and Oregon-specific legal status, covering FDA bulk-drug lists, 503A/503B compounding, state pharmacy board rules, and how to obtain a legitimate prescription.
BPC-157 occupies a gray area under federal law and California state regulations. This guide explains the FDA bulk-drug status, 503A/503B compounding rules, and the only legal access paths available to California residents in 2025.
A guide to BPC-157's federal regulatory status, Colorado-specific pharmacy law, and the legal paths a Colorado resident can use to obtain it under current 2024 to 2025 rules.
A guide to the legal status of BPC-157 in Michigan, covering FDA scheduling, 503A/503B compounding rules, the Michigan Board of Pharmacy, and how patients can legally access this peptide.
A breakdown of CJC-1295's legal status in Colorado, covering FDA compounding rules, state pharmacy board regulations, and how patients can legally access this growth hormone secretagogue.
A guide to the federal and Florida-state legal framework governing CJC-1295, including FDA compounding rules, 503A/503B pharmacy pathways, and how to get a lawful prescription.
A detailed look at PT-141 (bremelanotide) legal status in Arizona, covering FDA approval, federal scheduling, 503A/503B compounding rules, state pharmacy board regulations, and how Arizona residents can legally obtain a prescription.
A guide to the federal and Colorado-specific legal framework for PT-141 (Bremelanotide), including FDA approval status, 503A/503B compounding rules, and how to get a valid prescription.
A guide to the federal and Illinois-specific legal framework governing PT-141 (Bremelanotide), including FDA approval status, 503A/503B compounding rules, and how Illinois residents can obtain a lawful prescription.
A guide to the federal and Kentucky-specific legal status of PT-141 (Bremelanotide), how to obtain a valid prescription, and what compounding pharmacy rules apply in 2025.
A guide to the federal and Louisiana-specific legal framework for PT-141 (Bremelanotide), including FDA approval status, 503A/503B compounding rules, and how to get a valid prescription.
A guide to the federal and Minnesota-specific legal framework for PT-141 (Bremelanotide), including FDA approval status, compounding rules, and how to get a valid prescription.
A guide to the federal and Missouri-specific legal framework for PT-141 (Bremelanotide), including FDA approval status, 503A/503B compounding rules, and how to get a legitimate prescription.
A guide to the federal and Ohio-specific legal status of PT-141 (Bremelanotide), how prescriptions work, what compounding pharmacies can legally dispense, and how Ohio residents can access FDA-approved bremelanotide.
No sermorelin product is FDA-approved; Geref's approvals were withdrawn in 2009. Federal facts do not settle Illinois rules for compounded sermorelin.
A complete guide to the legal status of sermorelin in Oregon, covering federal FDA rules, 503A/503B compounding, Oregon state pharmacy board requirements, and how to get a legal prescription.
A guide to Sermorelin's legal status in Texas, covering federal FDA rules, 503A/503B compounding pharmacy law, state medical board requirements, and how to get a valid prescription.
A guide to Sermorelin's legal status in Virginia, covering federal FDA rules, 503A/503B compounding law, state pharmacy board requirements, and how to get a legitimate prescription.
A guide to TB-500 legal status in North Carolina, covering federal FDA rules, 503A/503B compounding pharmacy law, state pharmacy board regulations, and how patients can obtain TB-500 through a licensed provider.
A guide to TB-500's legal status in Pennsylvania, covering FDA scheduling, 503A/503B compounding rules, the state pharmacy board, and what a legitimate prescription pathway looks like.
A guide to the legal status of TB-500 (thymosin beta-4) in Washington State, covering FDA scheduling, 503A/503B compounding rules, state pharmacy board oversight, and how patients can legally obtain a prescription.
A guide to Egrifta (tesamorelin) legal status in Arizona, covering FDA approval, DEA scheduling, state pharmacy board rules, 503A/503B compounding, and how to get a legitimate prescription.
A board-reviewed guide to Egrifta (tesamorelin) legal status in Massachusetts, covering FDA approval, federal scheduling, 503A/503B compounding rules, and how to get a valid prescription.
A guide to the legal status of Thymosin Alpha-1 in Georgia, covering federal FDA rules, 503A/503B compounding pharmacy pathways, and how to get a legitimate prescription.
Thymosin alpha-1 is not FDA-approved and is in none of FDA's three pharmacy compounding categories. It is in category 3 for outsourcing facilities.
A comprehensive guide to FDA warning letters, USP <797> sterility rules, state board enforcement actions, and quality standards for compounded ipamorelin. Includes buyer guidance, HPLC purity benchmarks, and real regulatory history.
A clinically grounded guide to MK-677 (Ibutamoren) regulatory enforcement, compounding pharmacy quality standards, USP chapters, FDA warning letters, and how to evaluate a source before purchasing.
A breakdown of how PT-141 (Bremelanotide) is regulated, what separates research-chemical suppliers from licensed compounding pharmacies, and how to evaluate purity, sterility, and legal status before you buy.
A protocol for using CJC-1295 in ACL and ligament rehabilitation. Covers dosing, injection frequency, cycle length, monitoring labs, and what the evidence actually supports.
A protocol covering CJC-1295 dosing, stacking partners, cycle length, lab monitoring, and expected timelines for executives aged 40+ targeting sleep, cognition, and body composition.
A protocol for MK-677 (Ibutamoren) use in endurance athletes covering dose, timing, cycle length, monitoring labs, and the evidence base behind each recommendation.
A structured clinical protocol for using MK-677 (Ibutamoren) in recalcitrant chronic tendinopathy, covering dosing, cycle length, monitoring labs, and the evidence behind each recommendation.
Does MOTS-c improve ACL recovery? Separate mitochondrial and animal findings from human ligament healing, rehabilitation milestones, and return-to-sport evidence.
A step-by-step guide to reconstituting AOD-9604 peptide with bacteriostatic water, including dosing calculations, syringe selection, and storage protocols.